Outlook Therapeutics, Inc. (Nasdaq: OTLK), today announced the Scottish Medicines Consortium (SMC) approval of LYTENAVA™ (bevacizumab gamma) for the treatment of wet age-related macular degeneration ...

GLP-1 RA use was linked to a 2.21-fold risk of developing neovascular age-related macular degeneration// (nAMD) * Only 0.2% ...

A new study found a link between GLP-1s and a higher risk of neovascular age-related macular degeneration, an eye disease ...

Receiving the SMC recommendation of LYTENAVA™ (bevacizumab gamma) for patients with wet AMD is a significant milestone for our company and a testament to our commitment to improving patient outcomes,” ...

Age-related macular degeneration (AMD) is a major cause of blindness, especially in older adults. A key feature of early AMD ...

Jay Chhablani, MD, explains how 3D choroidal vessel segmentation transforms ophthalmology, enhancing disease diagnosis and ...

GLP-1 drugs like Ozempic are associated with a higher risk of developing wet age-related macular degeneration in people with ...

Metallic nanoparticles injected into the retina partly restored vision in blind mice and could work as a treatment for ...

Treatment for Parkinson's focuses on managing its many symptoms, as there is no cure. But a new stem cell therapy developed at Memorial Sloan Kettering Cancer Center for advanced Parkinson's is ...

Individualization of anti-VEGF treatment protocols can reduce treatment burden on patients with age-related macular degeneration ... than five letters of vision, new hemorrhages or fluid seen ...

The 2024 American Academy of Ophthalmology (AAO) Preferred Practice Patterns provide guidance for physicians about best practices in the treatment of age-related macular degeneration (AMD).